Users Coming Off Anti-Obesity Medications Regain Weight Far More Rapidly Than Dieters

Fresh analysis indicates that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle plans.

Findings released in a prominent health publication shows that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.

"Users buying such drugs should be aware of the danger of rapid rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.

This pace of regain implies a return to pre-treatment weight in about 18 months.

Weighing Therapies

The analysis, which reviewed 37 of studies involving over 9,000 of patients, contrasted the results of these new drugs with older methods.

Scientists emphasize that people who lose weight through lifestyle changes alone typically have a less rapid creep back—approximately 0.1 kg a month—after stopping.

Explaining the Rapid Rebound

Experts suggest the way of the jabs explains the heightened weight return.

GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.

"Long-term administration of the hormone levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating far more likely."

An Ongoing Disease?

The NHS recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.

Many experts say that, considering the high risk of weight regain, the therapy might need to be long-term.

This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term nature of obesity," akin to managing diseases like high blood pressure.

User Testimonies

Users who have discontinued the jabs describe a sudden resurgence of appetite.

"It felt as if a switch activating and you become extremely hungry," recalled a patient.

The struggle is compounded if patients have not developed lasting lifestyle or habit modifications during therapy.

Growing Adoption

Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is more common among women compared to men.
• The 40s and 50s age group shows the greatest level of interest.
• Many access the drugs through private prescriptions rather than the NHS.

Ultimately, clinicians stress that while the jabs are potent agents for shedding pounds, they are not a standalone fix and long-term success likely depends on combined behavioural changes.